Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TTK + LY6K + IMP-3 peptides
- Development stage
- Unknown
- Lead developer
- Kyoto University
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
TTK + LY6K + IMP-3 peptides is a cancer vaccine consisting of multiple peptides derived from three different Cancer-Testis antigens: TTK protein kinase (TTK), lymphocyte antigen 6 complex locus K (LY6K), and insulin-like growth factor (IGF)-II mRNA binding protein 3 (IMP-3). These peptides are mixed with incomplete Freund's adjuvant (IFA) and administered as a therapeutic cancer vaccine. The peptides are HLA-A24-restricted immunodominant epitopes that can induce cytotoxic T lymphocyte (CTL) responses against cancer cells expressing these antigens. The specific peptide sequences are TTK-567 (SYRNEIAYL), LY6K-177 (RYCNLEGPPI), and IMP-3-508 (KTVNELQNL). This combination has been studied primarily for esophageal squamous cell carcinoma (ESCC) patients who have been refractory to standard therapy.
- Other names
- TTK/LY6K/IMP-3 peptide vaccineUniversity of Yamanashi ESCC peptide vaccine
02
Targets
MHC II (Major histocompatibility complex class II receptor)TCR (T cell antigen receptor complex)
Beyond the preview
Go deeper on TTK + LY6K + IMP-3 peptides.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TTK + LY6K + IMP-3 peptides.